Skip to main content

Table 2 Characteristics of the clinical trials included in the systematic review with meta-analysis

From: The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis

First author name Country Gender Year Sample size Treatment Mean age Dose Measure Method of BC assay Pre-DAS-28 Post-DAS-28
Marcora [29] France M/F 2006 24 Group 1: etanercept
Group 2: MTX
NI Group 1: 50 mg/week
Group 2: 7.5~15 mg/week
Lean mass DEXA Group 1: 6.1 ± 0.7
Group 2: 5.8 ± 1.1
Group 1: t3.2 ± 1.5
Group 2: 3.1 ± 1.5
Engvall [30] Sweden M/F 2010 40 Group 1: MTX + SSZ + HCQ
Group 2: infliximab + MTX
Group 1: 59.5
Group 2: 56.0
Group 1: 20 mg/week MTX + 2000 mg/day SSZ + 400 mg/day HCQ
Group 2: 20 mg/week MTX + 3 mg/kg infliximab (weeks 0, 2, 6 and every 8 weeks)
Lean mass
App. lean mass
DEXA Group 1: 4.3
Group 2: 4.8
NI
  1. BIA bioimpedance, DEXA dual-energy X-ray absorptiometry, NI not informed, TNF tumor necrosis factor, BC body composition, M male, F female, MTX methotrexate, SSZ sulfasalazine, HCQ hydroxychloroquine